Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China

BackgroundReal-world evidence on dinutuximab beta for high-risk neuroblastoma (NB) in the Chinese pediatric patients remains limited. This study evaluated clinical efficacy and safety of dinutuximab beta as first-line maintenance therapy in a real-world setting.MethodsWe retrospectively analyzed ped...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Wen Zhao, Peiyi Yang, Jing Qin, Cheng Huang, Hongjun Fan, Mei Jin, Chao Duan, Ying Wu, Xisi Wang, Chunying Cui, Yan Su
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2026-02-01
Saila:	Frontiers in Oncology
Gaiak:	dinutuximab beta first-line maintenance GD2- antibody immunotherapy high-risk neuroblastoma pediatrics
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1765578/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!